Loading...
Although our government came to a grinding halt this year, I am glad to report that our editorial board has been busier than ever. Our choices of the most interesting and important dermatology stories of the past year are listed below. 2013 has been a banner year for all things therapeutic. In particular, we are witnessing an infusion of molecular medicine research: the use of targeted immune therapy in melanoma, the identification of genetic markers for predicting anti-TNF response in psoriasis, and the recognition of atypical protein kinase as a new therapeutic target in basal cell carcinoma. We also witnessed the value of consensus-based practices, such as propranolol treatment for infantile hemangioma. In some ways, these stories reflect trends in medicine overall. The pace of science is creating novel therapies at a dizzying pace, while the cost of medicine is forcing us to make the best choices based on evidence.
This has been an exciting year for us, as we embraced a broader collaboration with our colleagues in the NEJM Group and changed our name to NEJM Journal Watch Dermatology. We remain devoted to providing clinicians with the information they need to give their patients the best care — and, as part of NEJM Group, we are now poised to do so more effectively than ever. Our NEJM Journal Watch Dermatology editors will continue to pursue our goal of interpreting the latest research for application to clinical practice and reporting on science that will affect practice in the future. I hope you enjoy this Top Ten list.
Our Dermatology Top Stories of 2013 are:
The Use of Propranolol for Infantile Hemangioma: Consensus Recommendations
Adalimumab a “Proven” Therapy for Hidradenitis Suppurativa
Prophylaxis for Leg Cellulitis
Combined Immune Checkpoint Therapies Impressive in Advanced Melanoma
Genetic Markers That Identify TNF-Inhibitor Responders in Psoriasis
Cutaneous T-Cell Lymphoma and Defective Apoptosis: Fas Pathway
Chasing the Hedgehog: aPKC as a Potential Target in BCC
Risk for Metastasis and Death from Cutaneous Squamous Cell Carcinoma
Omalizumab Effectively Controls Chronic Idiopathic or Spontaneous Urticaria
Calcium-Channel Blockers and Chronic Eczematous Eruptions of the Aged
Happy New Year!